Litcius/Paper detail

Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation

Ahmed Babiker, Sarah Warner, Xiaobai Li, Emad A. Chishti, Eltaib Saad, Bruce Swihart, John P. Dekker, Morgan Walker, Alexander Lawandi, Sameer S. Kadri, Jennifer Adjemian, James Baggs, Edward Cox, Robert L Danner, John Dekker, John Farley, Anthony Fiore, David Hooper, John Jernigan, Amber Jessup, Sameer Kadri-Rodriguez, Eili Klein, Michael Klompas, Elaine Lai, Ramanan Laxminarayan, Tara Palmore, John H Powers, D. Rebecca Prevots, Chanu Rhee, Emily Ricotta, Arjun Srinivasan, Jeffrey R Strich, Anthony Suffredini

2024The Lancet Infectious Diseases23 citationsDOIOpen Access PDF

Topics & Concepts

LinezolidClindamycinMedicineRetrospective cohort studyInternal medicineRandomized controlled trialAntibioticsMicrobiologyVancomycinBiologyStaphylococcus aureusBacteriaGeneticsStreptococcal Infections and TreatmentsAntimicrobial Resistance in StaphylococcusNeonatal and Maternal Infections
Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation | Litcius